The Tardive Dyskinesia drugs in development market research report provides comprehensive information on the therapeutics under development for Tardive Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tardive Dyskinesia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tardive Dyskinesia and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Tardive Dyskinesia by six companies/universities/institutes. The top development phase for Tardive Dyskinesia is preclinical with three drugs in that stage. The Tardive Dyskinesia pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Tardive Dyskinesia pipeline products market are: Luye Pharma Group, Contera Pharma and Adeptio Pharmaceuticals.
The key targets in the Tardive Dyskinesia pipeline products market include Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2), 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A), and 5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D).
The key mechanisms of action in the Tardive Dyskinesia pipeline product include Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2) Inhibitor with four drugs in Pre-Registration. The Tardive Dyskinesia pipeline products include one routes of administration with the top ROA being Oral and one key molecule types in the Tardive Dyskinesia pipeline products market including Small Molecule.
Tardive Dyskinesia overview
Tardive dyskinesia is a is a movement disorder characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts caused by the blockade of dopamine receptors.
For a complete picture of Tardive Dyskinesia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
